• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

1. What Methocarbamol tablets are and what they are used for
2. What you need to know before you take Methocarbamol tablets
3. How to take Methocarbamol tablets
4. Possible side effects
5. How to store Methocarbamol tablets
6. Contents of the pack and other information

• if you are allergic to methocarbamol or any of the other ingredients of this medicine (listed in section 6)
• in the event of comatose or pre-comatose states
• if you suffer from nervous system (CNS) disorders
• if you suffer from pathological muscle weakness (myasthenia gravis)
• if you suffer from epilepsy

Talk to your doctor or pharmacist before taking methocarbamol:

• if you suffer from impaired kidney function and/or impaired liver function
• if you are having any medical investigations or tests as methocarbamol could interfere with the results. Tell your doctor that you are taking methocarbamol before you have the test

This medicinal product is not intended for use in children and adolescents as safety and efficacy in these patient groups have not been established.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

The concomitant administration of methocarbamol and centrally acting medicinal products such as barbiturates, opiate derivates and appetite suppressants may potentiate the effect of these medicines.

Methocarbamol can potentiate the effect of anticholinergic medicines such as atropine and some psychotropic medicines.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore methocarbamol must not be taken by patients with pathological muscle weakness (myasthenia gravis), who are being treated with pyridostigmine.

Consumption of alcohol during methocarbamol treatment may potentiate the effect of the medicine. Do not drink alcohol while you are taking Methocarbamol tablets.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Pregnancy

There is no experience available concerning the use of methocarbamol during pregnancy. The potential risk to humans is not known. You should not take methocarbamol during pregnancy.

Breast-feeding

It is not known whether methocarbamol and/or its metabolites pass into human milk. As a precautionary measure, you should not take Methocarbamol tablets if you are breast-feeding.

Fertility

No data are available concerning the influence of methocarbamol on human fertility.

Methocarbamol may affect your ability to drive and use machines. It may make you feel dizzy and drowsy.

Before you consider driving a vehicle or operating machinery, you should consider your state of health and the possible side effects of methocarbamol.

Therefore, you should not perform these activities until you have sufficient experience to know that you have no such side effects.

Methocarbamol tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

If you have taken too many Methocarbamol tablets, call your doctor straight away. The doctor will decide about the necessary actions.

If you forget to take a dose, take the next dose when it is due. Do not take a double dose to make up for a forgotten dose.

Inform your doctor if you intend to discontinue treatment with Methocarbamol tablets. Discontinuation is not expected to lead to any special effect.

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

• The active substance is methocarbamol.
  Each film-coated tablet contains 1500 mg methocarbamol.
• The other ingredients are:
  Tablet core: lactose monohydrate, croscarmellose sodium, sodium laurilsulfate, povidone, anhydrous colloidal silica, magnesium stearate.
  Film-coating: poly(vinylalcohol), titanium dioxide (E171), talc, macrogol 3350

Methocarbamol 1500 mg film-coated tablets are white, oblong, biconvex, film-coated tablets, 23 mm x 10 mm, with a score line on one side.

The score line is only there to help you break the tablet if you have difficulty swallowing it whole.

Methocarbamol 1500 mg film-coated tablets are available in packs containing 100 or 100 (2 packs of 50) film-coated tablets.

Not all pack sizes may be marketed.

The tablets in this pack are enclosed in PVC/aluminium blister strips.

The tablets in this pack are enclosed in ACLAR/aluminium blister strips.